Actelion stops enrollment in clazosentan trial

Actelion Ltd. (SIX:ATLN) discontinued enrollment in the Phase III CONSCIOUS-3 trial of clazosentan to prevent cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH) in patients who underwent coiling to secure their aneurysm. The move follows recent discussions with the study's steering committee that were undertaken after the endothelin A receptor antagonist missed the primary endpoint in the similar Phase III CONSCIOUS-2 trial to prevent cerebral vasospasm following aSAH. The company said it will still collect data from CONSCIOUS-3, which enrolled about 600 of a planned 1,500 patients. ...